Karine Sénéchal, PhD, is a R&D project manager that joined erytech Pharma in 2015 where she built her skills on preclinical development of biopharmaceutics. At erytech Pharma, she notably developed her expertise on the preclinical evaluation of a RBCs encapsulating an enzyme candidate for therapeutic use in oncology. Since 2021, she is working on the development of a new platform, ERYCEV, based on extracellular vesicles derived from red blood cells encapsulating therapeutic molecules.
Production and Biological Activity of RBC-derived Extracellular Vesicles Containing STING Agonist (ADU-S100) Using ERYCEV Platform
Monday, 24 October 2022 at 14:45
Add to Calendar ▼2022-10-24 14:45:002022-10-24 15:45:00Europe/LondonProduction and Biological Activity of RBC-derived Extracellular Vesicles Containing STING Agonist (ADU-S100) Using ERYCEV PlatformExtracellular Vesicles and Nanoparticle Therapeutics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
RBC-derived extracellular vesicles (RBCEVs) represent a new valuable
Drug Delivery System (DDS), due to their intrinsic properties (small
size, natural targeting to immune cells, biocompatibility…) and ease of
production[1]. This study evaluates the feasibility of producing
functional cargo-loaded RBCEVs from ERYCAPS pre-loaded RBCs[2].
To this end, RBCs encapsulating ADU-S100 or empty RBCs processed with
ERYCAPS (hypotonic dialysis encapsulation technology) were subjected to
physical vesiculation to produce ERYCEV-STINGa and ERYCEV respectively.
The RBCEVs produced and purified, analyzed by NTA, revealed a uniform
vesicles population of 95 nm mean size and 32 µg/mL mean ADU-S100
concentration in ERYCEV-STINGa. Luminal EVs markers TSG101 and ALIX were
successfully detected by western-blot. Additionally, FACS analysis of
surface markers showed moderate CD81 and CD235a levels and low CD47 and
PS levels. Functionality of produced RBCEVs were successfully
demonstrated in vitro. First, uptake of PKH67-labelled ERYCEV was
confirmed in both THP-1 monocytes and EMT6 murine tumor cells. Moreover,
THP1-derived macrophages phagocytosed pHrodo-labelled ERYCEV-STINGa,
which successfully activated STING pathway, demonstrated by luciferase
activity in THP1-Dual™ cells and type I interferon (IFN-beta)
production.
This first proof of concept to produce functional ERYCEV-STINGa supports
the development of ERYCEV platform by further investigating
pharmacologic properties in vivo and other cargo loading.
Add to Calendar ▼2022-10-24 00:00:002022-10-25 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle Therapeutics Europe 2022Extracellular Vesicles and Nanoparticle Therapeutics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-10-24 14:45:002022-10-24 15:45:00Europe/LondonProduction and Biological Activity of RBC-derived Extracellular Vesicles Containing STING Agonist (ADU-S100) Using ERYCEV PlatformExtracellular Vesicles and Nanoparticle Therapeutics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
